Pan Xiaoyan, Shi Jian, Hu Xue, Wu Yan, Zeng Liang, Yao Yanfeng, Shang Weijuan, Liu Kunpeng, Gao Ge, Guo Weiwei, Peng Yun, Chen Shaohong, Gao Xiaoxiao, Peng Cheng, Rao Juhong, Zhao Jiaxuan, Gong Cheng, Zhou Hui, Lu Yudong, Wang Zili, Hu Xiliang, Cong WenJuan, Fang Lijuan, Yan Yongxiang, Zhang Jing, Xiong Hui, Yi Jizu, Yuan Zhiming, Zhou Pengfei, Shan Chao, Xiao Gengfu
State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, China.
University of the Chinese Academy of Sciences, Beijing, China.
Cell Discov. 2021 Sep 7;7(1):82. doi: 10.1038/s41421-021-00320-y.
The pandemic of COVID-19 caused by SARS-CoV-2 has raised a new challenges to the scientific and industrious fields after over 1-year spread across different countries. The ultimate approach to end the pandemic is the timely application of vaccines to achieve herd immunity. Here, a novel SARS-CoV-2 receptor-binding domain (RBD) homodimer was developed as a SARS-CoV-2 vaccine candidate. Formulated with aluminum adjuvant, RBD dimer elicited strong immune response in both rodents and non-human primates, and protected mice from SARS-CoV-2 challenge with significantly reducing viral load and alleviating pathological injury in the lung. In the non-human primates, the vaccine could prevent majority of the animals from SARS-CoV-2 infection in the respiratory tract and reduce lung damage. In addition, antibodies elicited by this vaccine candidate showed cross-neutralization activities to SARS-CoV-2 variants. Furthermore, with our expression system, we provided a high-yield RBD homodimer vaccine without additional biosafety or special transport device supports. Thus, it may serve as a safe, effective, and low-cost SARS-CoV-2 vaccine candidate.
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019冠状病毒病大流行在不同国家传播一年多后，给科学和工业领域带来了新的挑战。结束大流行的最终方法是及时接种疫苗以实现群体免疫。在此，一种新型的SARS-CoV-2受体结合域（RBD）同二聚体被开发为SARS-CoV-2疫苗候选物。与铝佐剂一起配制后，RBD二聚体在啮齿动物和非人类灵长类动物中均引发了强烈的免疫反应，并保护小鼠免受SARS-CoV-2攻击，显著降低病毒载量并减轻肺部病理损伤。在非人类灵长类动物中，该疫苗可防止大多数动物呼吸道感染SARS-CoV-2并减少肺部损伤。此外，这种候选疫苗引发的抗体对SARS-CoV-2变体具有交叉中和活性。此外，利用我们的表达系统，我们提供了一种无需额外生物安全或特殊运输设备支持的高产RBD同二聚体疫苗。因此，它可能成为一种安全、有效且低成本的SARS-CoV-2疫苗候选物。
